Cervical Cancer in Europe & Central Asia
Death rates for Cervical Cancer across 58 countries in Europe & Central Asia.
| # | Country | Rate |
|---|
Cervical cancer is the fourth most common cancer in women globally and kills approximately 342,000 women per year. Persistent infection with high-risk human papillomavirus (HPV) types — principally HPV 16 and 18 — causes virtually all cases. Cervical cancer is unique among major cancers in that it is almost entirely preventable through vaccination and screening. The burden falls overwhelmingly on low- and middle-income countries, with sub-Saharan Africa accounting for roughly 20% of global deaths. In many African countries, cervical cancer is the leading cause of cancer death in women. Risk co-factors include HIV infection (which accelerates HPV-driven carcinogenesis), high parity, smoking, long-term oral contraceptive use, and co-infection with other sexually transmitted infections. The disparity between high-income countries (where screening and vaccination have dramatically reduced incidence) and low-income countries (where neither is widely available) represents a preventable tragedy. Europe and Central Asia benefit from relatively strong health systems and high physician density, but face ageing populations, rising non-communicable disease burdens, and persistent East-West health outcome gradients. In Europe & Central Asia, cervical cancer mortality is near global averages, though the region exhibits a marked gradient between Western European countries with low rates and Central Asian nations facing higher burdens.
HPV vaccination before sexual debut is over 90% effective against the most oncogenic HPV types and is the cornerstone of cervical cancer elimination. The WHO elimination strategy calls for 90% vaccine coverage, 70% screening coverage (twice per lifetime with HPV testing), and 90% treatment of pre-cancerous lesions and invasive disease. Screen-and-treat approaches using visual inspection with acetic acid (VIA) or HPV testing followed by thermal ablation are feasible in low-resource settings. Surgical treatment, radiation, and chemotherapy manage invasive disease. Several countries are on track to eliminate cervical cancer as a public health problem within the coming decades.
The mortality estimates presented on this page are derived from the Global Burden of Disease (GBD) study, produced by the Institute for Health Metrics and Evaluation (IHME). The GBD synthesizes data from vital registration systems, verbal autopsies, cancer registries, and surveillance networks across more than 200 countries and territories. Death rates are expressed per 100,000 population and are age-standardized, which adjusts for differences in age structure between populations so that comparisons across countries and over time reflect genuine differences in mortality risk rather than demographic composition.
The dataset typically covers the period from 1990 to 2023, although availability varies by country and cause. When interpreting the figures for cervical cancer in Europe & Central Asia, note that higher age-standardized rates indicate a greater mortality burden independent of whether a country's population is older or younger. Trends over time reveal whether public health interventions, economic development, and health system improvements have reduced or increased the toll of this condition in the region.
Cancer mortality data combine information from population-based cancer registries, vital registration systems, and statistical modeling where direct data are sparse. Incidence-to-mortality ratios and survival estimates help distinguish regions where high death rates stem from high incidence versus those where limited access to early detection and treatment drives poor outcomes. For cervical cancer across Europe & Central Asia, comparing mortality rates alongside screening coverage and treatment availability provides crucial context for understanding regional disparities.